DMAA
Drugs Made In America Acquisition Corp.10.36
-0.00-0.02%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
347.24MP/E (TTM)
-Basic EPS (TTM)
-Dividend Yield
0%Recent Filings
8-K
CEO ousted over sponsor withdrawals
Drugs Made In America Acquisition Corp. ousted CEO, Executive Chair, and board member Lynn Stockwell on February 28, 2026, after her sponsor withdrew over $1.1M from an affiliate's working capital—including $566K overpayment for unrelated expenses that can't be repaid. Roger Bendelac, a 30-year investment banking veteran, stepped in as new CEO. Leadership shakeup exposes sponsor risks.
8-K
Trust account confirmed intact
10-Q
Q3 FY2025 results
Drugs Made In America Acquisition Corp posted Q3 net income of $2.2M, driven by $2.4M interest from its $237.6M Trust Account, up sharply from a $0.1M loss y/y (derived), while offsetting $264K G&A costs. Nine-month net income hit $5.7M on $6.5M Trust interest versus $0.7M expenses, yielding $0.07 diluted EPS for both redeemable and non-redeemable shares—perfectly reconciled. Cash sits at $717 with $608K sponsor receivable; $6.9M deferred underwriting fee awaits deal close. Trust grows steadily. Yet SPACs face redemption risk if no pharma merger by April 2026.
8-K
CFO resigns, Elmasri appointed
Drugs Made In America Acquisition Corp. saw CFO Glenn Worman resign on October 8, 2025, with no disagreements cited. Saleem Elmasri steps in November 17 via Titan Advisory Services LLC, paid $42,000 yearly plus 100,000 shares. New CFO brings 20 years in pharma finance. Leadership stabilized swiftly.
10-Q
Q2 FY2025 results
Drugs Made In America Acquisition Corp. posted a solid Q2 net income of $2.3M, fueled by $2.4M in interest from its $235.2M trust account, while general and administrative costs ticked up to $132K from $331K in Q1. For the half-year, net income hit $3.5M on $4.0M interest, against $463K expenses— a stark turnaround from the $55K loss in its brief 2024 startup phase. Cash outside the trust sits at a lean $822, with a $252K working capital deficit, but the sponsor covers shortfalls via a $696K receivable. No debt weighs on the books. Yet the real pressure builds: nailing a pharma merger by April 2026, or it's liquidation time.
AAM
AA Mission Acquisition Corp.
10.65+0.03
DAAQ
Digital Asset Acquisition Corp.
10.17-0.01
ETHM
Dynamix Corporation
10.40-0.05
HCMA
HCM III Acquisition Corp.
10.08-0.01
IMAQ
International Media Acquisition
9.72+0.00
MAYA
Maywood Acquisition Corp.
10.31+0.00
MBAV
M3-Brigade Acquisition V Corp.
10.80-0.01
SDHI
Siddhi Acquisition Corp
10.25+0.00
SIMA
SIM Acquisition Corp. I
10.57+0.01
TDAC
Translational Development Acqui
10.42+0.00